RecruitingNCT07813208

Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival

Real-world Investigation of Diagnosis, Treatment, and Survival Status of Children With Ph+ ALL in China


Sponsor

The Children's Hospital of Zhejiang University School of Medicine

Enrollment

500 participants

Start Date

Aug 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The study aims to conduct a real-world investigation of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in China, assessing their diagnosis, treatment status, survival outcomes, and prognostic factors. The research will involve children diagnosed with Ph+ ALL between January 1, 2015, and December 31, 2024. Our objective is to understand the incidence and prognosis of CML-like ALL, compare the diagnostic and treatment differences between CML-like ALL and typical Ph+ ALL, and provide clinical evidence for standardized treatment of CML-like patients. Through a multicenter retrospective study, we hope to improve the diagnostic and treatment strategies for children with Ph+ ALL, enhancing patient survival rates and quality of life.


Eligibility

Min Age: 1 MonthMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with acute lymphoblastic leukemia, pediatric. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Month to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

The Children's Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07813208


Related Trials